Tumor Models Archives - Page 2 of 11

ADC Development: Preclinical Pharmacology Essentials

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...

Severe Hyperglycemia and Hyperlipidemia Alter Tumor Growth and Immune Profiles in Syngeneic Tumor Models

Studies have demonstrated that obesity can promote cancer progression through mechanisms that include chronic low-grade inflammation. Previous research with diet-induced...

Development of NK Humanized Mouse Models

Natural killer (NK) cells play a crucial role in the immune system and can recognize and kill cancer cells. Research...

Isogeneic Trop-2 Model for Evaluating Anti-Trop-2 ADCs

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...

HPV18-Related Cancer Model Development

Cancers, like cervical cancer and head & neck cancer, are strongly linked to human papillomavirus (HPV) infection. Targeting the HPV...

AACR 2025 Posters: Sneak Peek

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the...

Poster Presentations at AACR 2025

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present...

Synthetic Lethality Related Tumor Models

Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like...

Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies...

Knowledge Library